|
|
|
|
|
|
|
|
 |
|
ACN Newswire能提供全方位的服務。對於希望向媒體、業界和金融市場披露和傳播資訊的公司和組織，我們能為您安排即時的新聞發佈。ACN Newswire的新聞稿包括英文、簡體中文、繁體中文、韓文和日文等多種語言版本。
|
 |
|
|
|
|
| Saturday, 10 January 2026, 19:00 HKT/SGT | |
| |  | |
來源 Promicell | |
|
|
|
佛羅里達州邁阿密, 2026年1月10日 - (亞太商訊) - PromiCell公司（下稱「本公司」）作為臨床階段細胞免疫療法企業，憑藉獨特優勢致力於為癌症患者開發潛在根治性細胞療法。本公司今日宣布，首席醫療官John Lee醫學博士將發表核心資產PRO CAR -201A（一種針對STEAP1的CAR-T細胞療法）的臨床中期成果。該療法目前正於加州舊金山舉行的「2026生物科技展示會」進行全球首例人體臨床I期試驗，用於治療轉移性去勢抵抗性前列腺癌（mCRPC）。發表時間為太平洋標準時間2025年1月12日（週一）上午11時15分，地點位於舊金山會議中心法蘭西斯會廳（宴會廳層）。(宴會廳層)舉行。
關於普瑞美細胞公司
PromiCell是一家臨床階段細胞免疫療法公司，其候選產品代表高度差異化且創新的CAR-T與TCR-T平台，將分別應用於實體腫瘤與血液腫瘤領域。我們的創新產品管線包含STEAP1 CAR-T細胞、HA-1 TCR-T細胞及CD33 CAR-T細胞，適用於治療mCRPC、尤文氏肉瘤、復發性白血病及急性骨髓性白血病患者。我們的新世代嵌合抗原受體CAR-T細胞療法，旨在突破腫瘤逃逸、疾病復發及免疫逃避等關鍵機制。本公司科學團隊身為CAR-T細胞療法先驅，秉持「智勝癌症、為患者創造更多治癒機會」的使命。更多資訊請參閱：www.promicell.com 。
聯絡方式：
305-433-1287
anthony@promicell.com
消息來源：Promicell
話題 Press release summary
部門 健康与医药, Clinical Trials
http://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2026 ACN Newswire. All rights reserved. A division of Asia Corporate News Network
|
|
|
|
|
|
 |
|
Latest Press Releases
International Career Institute Marks 20 Years with 100 Scholarships to Support Flexible Online Study
Mar 24, 2026, 07:29 HKT/SGT
|
|
|
Doubleview Gold Clarifies Preliminary Economic Assessment Results for the Hat Project; Updated Scenario B NPV Increased to C$7.27 Billion
Mar 24, 2026, 04:59 HKT/SGT
|
|
|
OMP Positioned Highest for Both Completeness of Vision and Ability to Execute in the 2026 Gartner(R) Magic Quadrant(TM) for Supply Chain Planning Solutions: Process Industries
Mar 23, 2026, 23:15 HKT/SGT
|
|
|
Wellgistics Health Inc. Signs $105,000,000 Letter of Intent to Evaluate Potential Acquisition of Neuritek Therapeutics, Inc. which is Pioneering Innovative Therapies for Neurological and Psychiatric Disorders
Mar 23, 2026, 21:05 HKT/SGT
|
|
|
Essex Bio-Technology Reports Robust Results for FY2025, Turnover Soars 8.6% to HK$1814 million, Net Profit up 3.5% to HK$ 318.1 million, Total Dividend Increases by 16.7% to HK14 Cents per Share
Mar 23, 2026, 20:51 HKT/SGT
|
|
|
GMG Launches European Sales Team; G(R) Lubricant Patent Accepted for Europe
Mar 23, 2026, 20:29 HKT/SGT
|
|
|
Everest Medicines Enters into Asset Purchase Agreement for Etripamil Nasal Spray, Expanding Cardiovascular Footprint
Mar 23, 2026, 18:59 HKT/SGT
|
|
|
From SGD to Global Spending: How Singaporeans Can Avoid FX Fees While Travelling Overseas
Mar 23, 2026, 14:15 HKT/SGT
|
|
|
Fujitsu-developed traffic simulation system utilized in Maebashi City's public transportation planning
Monday, March 23, 2026 1:24:00 PM
|
|
|
Hitachi Receives the 2026 Catalyst Award, a Global Recognition for Building an Inclusive Organization
Monday, March 23, 2026 10:49:00 AM
|
|
|
|
|
More Press release >> |
|
|
|
| Copyright © 2026 ACN Newswire - Asia Corporate News Network |
|
|
頂部 | 關於我們 | 服務 | 合作夥伴 | 聯繫 | 隱私權政策 | 使用條款 | RSS
|
|
|
美國： +1 214 890 4418 | 中國： +86 181 2376 3721 | 香港： +852 8192 4922 | 新加坡： +65 6549 7068 | 東京： +81 3 6859 8575
|
|
|
|
|
| |
